<DOC>
	<DOCNO>NCT01121835</DOCNO>
	<brief_summary>Primary Objective : To demonstrate superiority strategy insulin glargine comparison strategy include premixed insulin term percentage patient reach HbA1c ( glycosylated hemoglobin ) 7 % end treatment experience document symptomatic hypoglycemia ( confirm Plasma Glucose ( PG ) 56 mg/dL ( 3.1 mmol/L ) ) 24-week treatment period , Type 2 diabetes patient fail lifestyle management oral agent . Secondary Objectives : To assess effect insulin glargine comparison premixed insulin : - Evolution HbA1c level treatment period Percentage patient reach target HbA1c &lt; 7 % experience document symptomatic hypoglycemia confirm Plasma Glucose ( PG ) 70 mg/dL ( 3.9 mmol/L ) - Percentage patient reach target HbA1c &lt; 6.5 % experience document symptomatic hypoglycemia confirm PG 56 mg/dL ( 3.1 mmol/L ) &gt; Percentage patient reach target HbA1c &lt; 6.5 % experience document symptomatic hypoglycemia confirm PG 70 mg/dL ( 3.9 mmol/L ) &gt; Evolution Fasting Plasma Glucose Evolution 7-point plasma glucose profile - Evolution weight - Hypoglycemia occurrence - Dose insulins - Evolution liver function - Overall safety</brief_summary>
	<brief_title>Insulins Glargine gluLisine strAtegy Versus Premixed Insulin strAteGy : cOmparative Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Type 2 diabetes diagnose 1 year Insulin naïve Treated lifestyle intervention oral antidiabetic drug , least metformin maximum tolerate dose ( minimum dose 1g/day ) , least 3 month HbA1c ≥ 7.0 % ≤ 10.5 % Body mass index ( BMI ) ≤ 40 kg/m2 Ability willingness perform plasma glucose ( PG ) monitoring use sponsorprovided glucose meter complete patient diary Willingness ability comply study protocol Signed informed consent obtain prior study procedure Exclusion criterion : Treatment glucagonlike peptide1 ( GLP1 ) agonists 3 month prior study entry Previous treatment insulin ( except treatment gestational diabetes brief treatment insulin le 1 week ) Diabetes type 2 diabetes ( e.g . type 1 diabetes , diabetes secondary pancreatic disorder , drug chemical agent intake ) Pregnant lactate woman ( woman childbearing potential must negative pregnancy test study entry medically approve contraception method ) Hospitalized patient ( except routine diabetes checkup ) Active proliferative retinopathy , define photocoagulation vitrectomy occurrence 6 month prior study entry , unstable ( rapidly progress ) retinopathy may require photocoagulation surgical treatment study , document retina examination , 2 year prior study entry History sensitivity study drug drug similar chemical structure Impaired renal function : creatinine clearance &lt; 60ml/min Impaired liver function ( ALT , AST &gt; 3 x upper limit normal range ) Severe gastrointestinal disease Treatment corticosteroids potential systemic action within 3 month prior study entry Likelihood require treatment study permit Treatment investigational product 30 day prior study entry Alcohol drug abuse within last 5 year The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>